NICE endorses use of Roche's MabThera in rare autoimmune disorder

10/4/2013 | PharmaTimes (U.K.)

The U.K. National Institute for Health and Care Excellence published draft guidance endorsing the use of Roche's MabThera as a treatment for some adults with anti-neutrophil cytoplasmic antibody-associated vasculitis. The treatment is a cost-effective use of the National Health Service's resources if further cyclophosphamide treatment would go beyond the maximum cumulative dose, NICE concluded.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC